GSK_Annual_Report_2021

At GSK, we continually pioneer innovation and pursue our ambition of facilitating our patients do more, feel better, and live longer. Our constant pursuit of technical and scientific excellence results in a steady stream of product innovations that meet the critical needs of our patients. Fluarix Tetra The World’s first Quadrivalent Influenza Vaccine (QIV) Influenza is a viral infection of the respiratory system which leads up to 50 lakh cases of severe illness, and up to 7 lakh deaths every year globally. QIVs are found to offer broader protection compared to Trivalent Influenza Vaccines (TIV) in protecting against influenza. Fluarix Tetra was launched in India in September 2020.  Global pioneer for single dose 0.5 ml formulation  100 quality tests undertaken for each batch  Only QIV backed by strong clinical data across 5 influenza seasons  Only QIV with India efficacy data  More than 24,000 subjects tested globally, including India  25 crore doses sold worldwide and counting  Manufactured at the state-of-the-art facility in Germany 9 Annual Report 2020-21